BVT Knock-Out ABBV/ DE000VM6U8X0 /
| 2024-05-22 9:38:05 PM | Chg.- | Bid8:04:09 AM | Ask8:04:09 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.27EUR | - | 1.23 Bid Size: 3,000 |
1.31 Ask Size: 3,000 |
AbbVie Inc | 146.69 USD | 2078-12-31 | Call |
GlobeNewswire
05-22
Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire
05-22
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-22
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-22
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...
GlobeNewswire
05-21
BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...
GlobeNewswire
05-21
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
05-17
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...
GlobeNewswire
05-16
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
GlobeNewswire
05-14
CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...
GlobeNewswire
05-14
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-14
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
05-09
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
